Bentley, Anthony; Filipovic, Ivana; Gooch, Katherine; … - In: Health Economics Review 3 (2013) 1, pp. 1-12
Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources. </AbstractSection> Copyright Bentley et al.; licensee Springer. 2013